Prospective multicentre accuracy evaluation of the FUJIFILM SILVAMP TB LAM test for the diagnosis of tuberculosis in people living with HIV demonstrates lot-to-lot variability
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0303846 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Rita Székely und 29 weiteren Autor:innen. Beteiligte Einrichtung: FIND, The Global Alliance for Diagnostics, Geneva, Switzerland. Hauptthemen laut MEDLINE: HIV Infections, Tuberculosis. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, FIC NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
There is an urgent need for rapid, non-sputum point-of-care diagnostics to detect tuberculosis. This prospective trial in seven high tuberculosis burden countries evaluated the diagnostic accuracy of the point-of-care urine-based lipoarabinomannan assay FUJIFILM SILVAMP TB LAM (FujiLAM) among inpatients and outpatients living with HIV. Diagnostic performance of FujiLAM was assessed against a mycobacterial reference standard (sputum culture, blood culture, and Xpert Ultra from urine and sputum at enrollment, and additional sputum culture ≤7 days from enrollment), an extended mycobacterial reference standard (eMRS), and a composite reference standard including clinical evaluation. Of 1637 participants considered for the analysis, 296 (18%) were tuberculosis positive by eMRS. Median age was 40 years, median CD4 cell count was 369 cells/ul, and 52% were female. Overall FujiLAM sensitivity was 54·4% (95% CI: 48·7–60·0), overall specificity was 85·2% (83·2–87·0) against eMRS. Sensitivity and specificity estimates varied between sites, ranging from 26·5% (95% CI: 17·4%–38·0%) to 73·2% (60·4%–83·0%), and 75·0 (65·0%–82·9%) to 96·5 (92·1%–98·5%), respectively. Post-hoc exploratory analysis identified significant variability in the performance of the six FujiLAM lots used in this study. Lot variability limited interpretation of FujiLAM test performance. Although results with the current version of FujiLAM are too variable for clinical decision-making, the lipoarabinomannan biomarker still holds promise for tuberculosis diagnostics. The trial is registered at clinicaltrials.gov (NCT04089423).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- FIND, The Global Alliance for Diagnostics, Geneva, Switzerland.
- Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
- Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
- Public Health Group, Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
- Department of Pathology, Kamuzu University of Health Sciences, Blantyre, Malawi.
- Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
ORCID-Profile: Bianca Sossen, Satoshi Mitarai, Andrew D Kerkhoff, Peter MacPherson, Morten Ruhwald
Förderung
- Wellcome Trust
- FIC NIH HHS
- NIAID NIH HHS
- Global Health Innovative Technology Fund
- KfW Entwicklungsbank
- Department of Foreign Affairs and Trade, Australian Government
- Netherlands Enterprise Agency
- South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation (NRF) of South Africa
Zitieren
APA
Székely, R., Sossen, B., Mukoka, M., Muyoyeta, M., Nakabugo, E., Hella, J., Nguyen, H. V., Ubolyam, S., Chikamatsu, K., Macé, A., Vermeulen, M., Centner, C. M., Nyangu, S., Sanjase, N., Sasamalo, M., Dinh, H. T., Ngo, T. A., Manosuthi, W., Jirajariyavej, S., …, & FujiLAM Study Consortium (2024). Prospective multicentre accuracy evaluation of the FUJIFILM SILVAMP TB LAM test for the diagnosis of tuberculosis in people living with HIV demonstrates lot-to-lot variability. PLOS ONE. https://doi.org/10.1371/journal.pone.0303846
Vancouver
Székely R, Sossen B, Mukoka M, Muyoyeta M, Nakabugo E, Hella J, et al. Prospective multicentre accuracy evaluation of the FUJIFILM SILVAMP TB LAM test for the diagnosis of tuberculosis in people living with HIV demonstrates lot-to-lot variability. PLOS ONE. 2024. doi:10.1371/journal.pone.0303846
BibTeX
@article{Szkely2024,
author = {Székely, Rita and Sossen, Bianca and Mukoka, Madalo and Muyoyeta, Monde and Nakabugo, Elizabeth and Hella, Jerry and Nguyen, Hung Van and Ubolyam, Sasiwimol and Chikamatsu, Kinuyo and Macé, Aurélien and Vermeulen, Marcia and Centner, Chad M and Nyangu, Sarah and Sanjase, Nsala and Sasamalo, Mohamed and Dinh, Huong Thi and Ngo, The Anh and Manosuthi, Weerawat and Jirajariyavej, Supunnee and Mitarai, Satoshi and Nguyen, Nhung Viet and Avihingsanon, Anchalee and Reither, Klaus and Nakiyingi, Lydia and Kerkhoff, Andrew D and MacPherson, Peter and Meintjes, Graeme and Denkinger, Claudia M and Ruhwald, Morten and FujiLAM Study Consortium, FujiLAM Study Consortium},
title = {Prospective multicentre accuracy evaluation of the FUJIFILM SILVAMP TB LAM test for the diagnosis of tuberculosis in people living with HIV demonstrates lot-to-lot variability},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0303846}
}
EUVIMED